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Abstract  
Amphetamine (AM) is a powerful psychostimulant existing in two enantiomeric forms. 
Stereoselective analysis of AM in biosamples can assist clinicians and forensic experts in 
differentiating between abuse of illicitly synthesized racemic AM and ingestion of 
pharmaceutical AM formulations containing either S-AM or different proportions of the S- and 
R-enantiomers. Therefore, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
method for quantifying AM enantiomers in urine was newly developed. The method comprised 
dilution with water, followed by injection of the diluted sample onto an achiral C18 trapping 
column for purification and subsequent backflush elution to a chiral Lux 3 µm AMP LC column 
by means of a switching valve. An isocratic mobile phase of 25% acetonitrile in 0.1 M aqueous 
ammonia was used for enantiomeric separation. Injection, cleanup and backflush of the next 
sample were performed before the previous sample had eluted from the analytical column, thus 
enabling simultaneous enantioseparation of up to three samples within the analytical column. 
This novel chromatographic concept allowed for increased sample throughput by accelerating 
both the sample preparation and the LC analysis. Analyte detection was accomplished by 
electrospray ionization in positive ion mode and selected reaction monitoring using a triple-stage 
quadrupole mass spectrometer. The method was successfully validated through assessment of its 
linearity, lower limit of quantification, accuracy and precision, selectivity, matrix effect, carry-
over, dilution integrity, and re-injection reproducibility. Linearity ranged from 0.05 – 25 mg/L for 
both enantiomers. Proof of the method included analysis of urine samples obtained from drug 
abusers and patients receiving an S-AM prodrug. 
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Introduction 
Amphetamine (AM) is a potent stimulant of the central nervous system (CNS) and has been 
established as an effective treatment for attention deficit hyperactivity disorder (ADHD), as well 
as other CNS disorders such as narcolepsy. Its powerful stimulatory action does not only provide 
therapeutic efficacy, but it also responsible for AM’s adverse effects and high potential for 
recreational abuse. As a result of the United Nations Convention on Psychotropic Substances of 
1971, AM became a controlled substance in many countries and is available for treatment by 
prescription only [1-3]. Nevertheless, AM abuse is widespread, with global AM seizures 
fluctuating between about 20 and 33 tons annually since 2009 [4]. 
As a molecule with a single chiral center, AM exists in two optically active forms, i.e. the S-(+)- 
(or d-) and R-(-)- (or l-) enantiomers, which differ in their pharmacological characteristics. While 
the R-enantiomer produces more cardiovascular and peripheral effects, the S-enantiomer has 
stronger stimulant properties. Illicit production of AM generally yields a 50:50 racemic mixture 
of the two enantiomers [5, 6]. Currently available pharmaceutical formulations of AM, on the 
other hand, primarily contain either S-AM (e.g. Dexedrine
®
, ProCentra
®
, Elvanse
®
) or different 
proportions of the S- and R-enantiomers (e.g. Adderall
®
, 3:1 mixture of S- and R-AM) [1, 2]. 
Thus, the determination of the enantiomeric composition of AM in biological samples may help 
to distinguish between the illicit consumption of street AM and the legitimate use of AM 
medication, which is of great relevance in clinical and forensic toxicology. With the approval of 
the S-AM prodrug Elvanse
®
 (lisdexamfetamine [L-lysine-dextroamphetamine] dimesylate) at the 
beginning of 2014, AM-based medication for ADHD treatment also became available in 
Switzerland. Therefore, our laboratory finds itself confronted with a growing demand for an 
enantioselective method for the analysis of AM in forensically relevant biological matrices. 
Various analytical methods have been reported for the enantioselective determination of AM in 
whole blood, plasma, urine, oral fluid, and hair. The most extensively used technique has been 
gas chromatography (GC) coupled with mass spectrometry (MS), comprising off-line 
derivatization with a chiral reagent and separation of the resulting diastereomeric derivatives on 
an achiral column, as recently reviewed [7]. Enantioseparation of AM after derivatization to 
diastereomers has also been achieved on conventional liquid chromatography (LC) stationary 
phases [8, 9]. A possible drawback of this approach is that such derivatizing reagents might be 
less than 100% enantiomerically pure and that additional sample pretreatment steps are needed. 
[10]. Using chiral stationary phases eliminates the need for tedious and time-consuming 
derivatization steps, enabling direct enantioseparation. Chiral LC methods using MS, UV or 
fluorescence detection have been reported for the stereoselective analysis of AM in hair [11-13] 
and urine [14-16]. AM enantiomers have also been separated by capillary electrophoresis (CE) 
using chiral selectors as mobile phase additives and MS or UV detection [17-19]. However, 
compared to GC and LC, CE is much less commonly implemented in forensic laboratories. 
In this work, we present a straightforward and sensitive LC-MS/MS method which uses a new 
chiral stationary phase for separation and quantification of S- and R-AM in urine, a widely 
employed matrix for drug of abuse testing. We developed a novel chromatographic concept 
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which allows for accelerated sample preparation and LC analysis without compromising the 
analytical quality, thus overcoming the drawbacks of time-consuming sample preparation 
procedures and long analytical run times from which previously reported methods have suffered. 
Main aspects of the presented concept are on-line sample purification using a trapping column 
and switching valve, and simultaneous analysis of several samples within the same analytical 
column. The validated method was applied to urine specimens obtained from forensic toxicology 
cases. 
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Material and methods 
Chemicals and reagents 
Standard solutions of (±)-AM, S-AM, R-AM (1 g/L) and (±)-AM-d5 (100 mg/L, deuterium atoms 
on side chain) in methanol were obtained from Cerilliant (Round Rock, TX, USA). The racemate 
was used for calibration and quality control, and the pure enantiomers for peak identification. 
Acetonitrile (99.9%, HPLC gradient grade) was purchased from Acros Organics (Chemie 
Brunschwig, Basel, Switzerland) and ammonium hydroxide solution (25%, for analysis 
EMSURE
®
) from Merck (Grogg Chemie, Stettlen, Switzerland). Water was purified in-house 
with a Milli-Q water system from Millipore (Zug, Switzerland). Blank urine was provided by 
healthy and abstinent volunteers. 
 
Calibration, quality control and internal standard solutions 
Serial dilution of the (±)-AM standard solution in acetonitrile yielded working solutions at 0.75, 
1.5, 7.5, 15, 75, 150, and 375 mg/L per enantiomer for calibration and at 0.75, 2.25, 60, and 300 
mg/L for quality control (QC). Separate dilution series were used for the preparation of 
calibration and QC working solutions. Adding 5 µL of working solution to 70 µL of blank urine 
created calibration samples at 0.05, 0.1, 0.5, 1, 5, 10, and 25 mg/L and QC samples at 0.05, 0.15, 
4, and 20 mg/L per enantiomer. Calibration and QC samples were freshly prepared on each day 
of analysis. An internal standard working solution at 10 mg/L was obtained by 1:10 dilution of 
the (±)-AM-d5 reference material in acetonitrile. All working solutions were stored at about −20 
°C in polypropylene tubes. 
 
Sample preparation 
Fifteen microliters of internal standard working solution were added to 75 μL of urine sample 
(calibration, QC, or unknown sample) in an autosampler vial. After adding 1.41 mL of water, the 
mixture was thoroughly vortexed and 1.0 μL was injected into the column-switching LC-MS/MS 
system for quantitative analysis.  
 
Liquid chromatography 
Column-switching liquid chromatography was performed using an UltiMate 3000 HPLC system 
(Dionex, Olten, Switzerland) equipped with two SRD-3600 solvent racks, two HPG-3200RS 
binary pumps, an ISO-3100SD isocratic pump, a WPS-3000TRS plate autosampler operated at 8 
°C, a TCC-3000RS column compartment set to 30 °C and fitted with a 6-port switching valve. 
Mobile phase A was 0.1 M aqueous ammonia (pH 11) which was freshly prepared on each day of 
analysis, and mobile phase B was acetonitrile.  
The chromatographic setup is represented in Fig. 1. From a 100 µL autosampler loop, the 
prepared sample was loaded onto the trapping column (Gemini 5 µm C18 110 Å, 10 x 2 mm, 
Phenomenex, Torrance, CA, USA) with a 400 µL/min flow of 20% B delivered by binary pump 
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1. To enhance the retention of the analytes on the trapping column, the injection solution was 
diluted via a T-union with a 200 µL/min flow of mobile phase A delivered by the isocratic pump 
(Fig. 1a). After 1 min, the valve was switched and the retained analytes were transferred in 
backflush mode to the chiral analytical column (Lux 3 µm AMP LC column, 150 x 3.0 mm, 
Phenomenex, Torrance, CA, USA), fitted with a KrudKatcher Ultra in-line filter (Phenomenex, 
Torrance, CA, USA). Elution and detection of the analytes was performed under isocratic 
conditions with a 500 µL/min flow of 25% B delivered by binary pump 2. In the elution 
configuration (Fig. 1b), the flows of the isocratic pump and binary pump 1 were directed into the 
waste and were then reduced to 20 µL/min. After 4 min of elution onto the analytical column, the 
valve was switched back to the loading position and the flow rates of the isocratic and binary 
pump 1 were increased to their initial values, without flow interruption on the analytical column. 
After re-equilibration for 1 min, the next sample was injected and the HPLC program was run 
again. The last run of a sequence was extended to 12 min in order to ensure elution of all samples 
from the analytical column. Details on the HPLC program for the column-switching 
chromatographic procedure are given in Table 1. Chromeleon software version 6.8 (Thermo 
Fisher Scientific, Waltham, MA, USA) was used to control the HPLC system.  
To prevent the accumulation of possible impurities during the isocratic use, column washing was 
performed after injecting 15 urine samples by running a linear gradient from 20 to 95% B and 25 
to 95% B, respectively (Table 2). The chromatographic system was held in the loading 
configuration (Fig. 1a) and a 1 µL aliquot of mobile phase A was injected. 
 
Tandem mass spectrometry 
A 5500 QTRAP hybrid triple quadrupole/linear ion trap mass spectrometer equipped with a 
Turbo V ion source (SCIEX, Brugg, Switzerland) was operated in selected reaction monitoring 
(SRM) mode for mass spectrometric detection. Electrospray ionization was performed in positive 
ion mode using the following settings: ion source voltage, 3500 V; source temperature, 600 °C; 
curtain gas, 40; collision gas, medium; gas 1, 40; and gas 2, 60 (arbitrary units for the gas 
settings). Optimal SRM parameters were determined by direct infusion of a 100 μg/L methanolic 
solution of (±)-AM and (±)-AM-d5, respectively, at a flow rate of 10 μL/min using a syringe 
pump. Quantifier and qualifier mass transitions were selected on the basis of signal intensity. 
Monitored transitions were m/z 136.1 → 91.0 (quantifier) and m/z 136.1 → 119.0 (qualifier) for 
AM enantiomers, and m/z 141.1 → 93.0 for AM-d5 enantiomers. Collision energies were 26, 11 
and 26 eV, respectively. Declustering potential, entrance potential, collision cell exit potential 
and dwell time were 45 V, 10 V, 8 V and 150 ms, respectively, for all transitions. Analyst 
software version 1.6.2 (SCIEX, Brugg, Switzerland) was used for data acquisition and 
processing. The HPLC system and the mass spectrometer were controlled separately. MS/MS 
data acquisition was started 2 min after sample injection and lasted for 6 min. 
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Validation 
Validation criteria included linearity, intra- and inter-assay accuracy and precision, lower limit of 
quantification (LLOQ), selectivity, matrix effect, carry-over, dilution integrity, and re-injection 
reproducibility. Method validation was conducted according to international guidelines [20, 21] 
and as previously reported [22]. 
Linearity was assessed by analyzing duplicate calibration curves on three different days (n = 6). 
Calibration curves were generated by calculating the peak area ratio of analyte to internal 
standard for each analyte concentration (x) and were fit by unweighted linear least-squares 
regression and linear least-squares regression applying a 1/x and 1/x
2
 weighting factor, 
respectively. The most appropriate calibration model was chosen by inspection of the percentage 
relative error (%RE) which compares the concentration calculated from the regression equation 
with the target value [23]. Linearity was acceptable if the correlation coefficient (r) was at least 
0.99 and calibrators quantified within ± 15% of the nominal concentration (± 20% at LLOQ). 
Accuracy and precision were evaluated at low, mid, and high QC level as well as at the LLOQ 
level. Intra-assay accuracy and precision were assessed with six replicates per level in a single 
run. For the determination of the inter-assay accuracy and precision, six replicates of each QC 
sample were prepared and analyzed on three different days (n = 18). QC concentrations were 
calculated from daily calibration curves. Accuracy was defined as the percentage of the mean 
concentration of all replicates from the corresponding nominal concentration and was expected to 
be 85 – 115% (80 – 120% at LLOQ). Precision was expressed as percent coefficient of variation 
(% CV) of the calculated concentrations and should not exceed 15% (20% at LLOQ). 
For evaluation of method selectivity, blank urine specimens from six different donors were 
analyzed to identify possible interferences from endogenous compounds. In addition, selectivity 
was assessed by spiking the different blank urine sources to the LLOQ level. Selectivity was 
demonstrated if any signal in the blank samples was ≤ 20% of the LLOQ and ≤ 5% internal 
standard response and if the LLOQ samples quantified within ± 20% of the nominal 
concentration.  
Matrix effects were investigated through post-column infusion experiments. A methanolic 
solution containing (±)-AM and (±)-AM-d5 at a concentration of 200 µg/L each was infused 
continuously at a flow rate of 30 µL/min via a T-union into the HPLC eluent during the LC-
MS/MS analysis of blank urine samples from six different subjects. The signals of the monitored 
SRM transitions were examined for any suppression or enhancement over the entire 
chromatographic run. 
Carry-over was assessed by injecting a blank specimen immediately after the highest calibration 
standard in three independent runs. Absence of carry-over was verified if any response in the 
blank specimens was ≤ 20% of the LLOQ and ≤ 5% of the internal standard response.  
Dilution integrity was evaluated by diluting urine samples spiked with (±)-AM at a concentration 
of 75 mg/L with blank urine to achieve 1:10 and 1:5 (v/v) dilution (n = 6 per dilution factor). 
Internal standard solution was added and samples were processed as described. Dilution integrity 
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was considered acceptable if specimens quantified within ± 15% of expected diluted 
concentrations and with acceptable precision (≤ 15% CV). 
Re-injection reproducibility was examined with six replicates per QC level. These samples were 
analyzed immediately after sample preparation and were then stored at 8 °C in the autosampler. 
After 6 days, they were re-injected and quantified against the re-injected calibration curve. 
Reproducibility was proven if re-analyzed samples quantified within ± 15% of the first 
measurement. 
 
Application to authentic urine samples 
The presented method was applied to 67 urine specimens which were obtained from forensic 
toxicology cases and were AM positive by our routinely used qualitative enzyme immunoassay 
(Immunanalysis, Pomona, CA, USA, 500 μg/L cutoff for AM). In all the cases considered for this 
work, the positive immunoassay results for urine were followed by quantitative analysis of AM, 
methamphetamine (MA) and four amphetamine-derived designer drugs in whole blood by a well-
established GC-MS method in our laboratory. In 42 cases, both the urine and blood samples were 
positive for AM only. In two of these cases, the persons concerned had been treated with 
clinically relevant doses of Elvanse
®
 (30 – 70 mg/day). In the other 40 cases with only AM 
present, AM abuse was assumed. In the remaining 25 cases, both the urine and blood samples 
were positive for AM and MA, indicating that the consumed drug was MA, with the detected AM 
being a metabolite of MA [24]. During the time between the immunological screening and the 
enantioselective analysis with the presented method (1 – 12 months), the urine samples were 
stored at -20 °C. 
Reliability and reproducibility of the AM enantiomer concentrations in authentic urine samples 
were verified by re-analyzing a random selection of 23 samples after storage at about -20 °C for 
two to three weeks. The difference between the initial concentration and the concentration 
measured during reanalysis should not exceed 20% of their mean for at least 67% of the repeats, 
as it is generally required for valid sample reanalysis [21]. 
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Results and discussion 
Method development and analytical performance 
We have developed an analytical method for the enantioselective determination of R- and S-AM 
in human urine. Our goals of method development were minimal sample preparation and a short 
analysis time. To meet these criteria, we used a column-switching HPLC system consisting of an 
achiral reversed-phase trapping column and a chiral analytical column combined with tandem 
mass spectrometry. In comparison to existing GC-MS methods [6, 25-29], chiral LC-MS/MS 
enables direct separation and analysis of AM enantiomers, rendering time-consuming sample 
derivatization steps unnecessary. 
Sample purification was achieved on-line by using a trapping column, limiting off-line sample 
pretreatment to a simple dilution step with water. With the mobile phases described, the analytes 
were retained and concentrated on the trapping column, while salts and other urine constituents 
were washed away to waste. Compared to the off-line solid-phase extraction and liquid-liquid 
extraction procedures commonly used for preparing urine samples for stereoselective AM 
analysis [6, 16-19, 25-29], on-line sample cleanup has the advantages of being time- and cost-
efficient and less prone to sample contamination, human error and reproducibility problems. In 
addition, the use of a trapping column allows for large injection volumes without affecting the 
chromatographic performance of the analytical column, thus making the presented method easily 
transferable between different mass spectrometers by simply adjusting the injection volume 
according to the instrument’s sensitivity. 
The AM enantiomers were retained as racemic mixture on the achiral C18 trapping column. 
Switching of the valve backflushed the enriched and cleaned analytes and transferred them onto 
the analytical column for enantioselective separation and detection. Chiral separation was 
achieved on a Lux 3 µm AMP LC column containing a novel stationary phase which was 
specifically designed for the chiral analysis of AM and substituted AMs. Various mobile phase 
conditions were investigated to optimize analyte trapping and enantioseparation. 
Enantioselectivity was found to be pH dependent and was optimal under strongly alkaline 
conditions. Therefore, 0.1 M aqueous ammonia (pH 11) was used for pH adjustment of the 
mobile phase. The employed Gemini C18 trapping column is characterized by enhanced stability 
under extreme pH conditions and offers good retention of basic compounds at an alkaline pH 
value. Binary mixtures of aqueous ammonia and acetonitrile or methanol as well as ternary 
mixtures of aqueous ammonia, acetonitrile and methanol were tested in the isocratic and gradient 
elution mode. Enantioseparation was better in the isocratic elution mode than with gradient 
elution, and methanol as organic modifier produced somewhat higher enantioselectivity than 
acetonitrile and acetonitrile/methanol mixtures. However, acetonitrile gave sharper peaks, shorter 
retention times and lower backpressure while still providing sufficiently high enantioselectivity. 
Thus, isocratic conditions with acetonitrile as organic solvent were chosen. 
Column washing by running a gradient was only carried out after every 15 injections, which 
saved column re-equilibration time and proved to be sufficient to avoid accumulation of 
impurities. Performing isocratic elution and intermittent column washing allowed for 
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simultaneous analysis of several samples on the analytical column. Injection, cleanup and 
backflush of a sample were carried out before the previous sample had completely eluted from 
the analytical column, resulting in up to three samples migrating through the analytical column at 
once. Careful optimization of the injection and valve switching times (Table 1) ensured that no 
intermixing of the sample bands took place. Using this approach, an average sample analysis time 
of 6.4 min could be achieved. Compared to a conventional sequential analysis with the same 
HPLC system, this multiple-injection-approach significantly increases sample throughput, 
resulting in a shorter analysis time than the existing methods for stereoselective determination of 
AM in urine [6, 14-19, 25-29]. Other approaches such as parallel analysis with several columns 
would require additional HPLC columns, additional pumps and a second valve. 
The presented method achieved sufficient separation of the two AM enantiomers with average 
retention times of 1.92 min and 2.90 min, respectively. Retention times were highly reproducible 
and stable over a large number of injections. By analyzing enantiomerically pure standards, the 
earlier eluting peak was identified as R-AM (Fig. 2).  
 
Validation 
Evaluation of relative percentage errors showed that linear least-squares regression with a 1/x 
weighting factor was the most appropriate calibration model. The LLOQ, defined as the lowest 
concentration that can be quantified with acceptable accuracy (80 – 120%) and precision (≤ 20% 
CV), was determined to be 0.05 mg/L for both AM enantiomers. An extracted ion chromatogram 
of a urine sample spiked at the LLOQ level is presented in Fig. 2b. The method was linear over 
the tested calibration range (0.05 – 25 mg/L for both AM enantiomers) with correlation 
coefficients r ≥ 0.994 when employing 1/x weighting. Back-calculated concentrations of the 
calibration samples were within ± 13.2% of the target concentrations (± 17.2% at LLOQ). 
Both AM enantiomers demonstrated acceptable accuracies and precisions at all QC 
concentrations (Table 3). Accuracy ranged from 90.1 to 103.0% and precision was less than 
14.1% CV for the two AM enantiomers at each QC level. 
The method proved to be selective. No significant endogenous interferences could be detected at 
the expected retention times of the AM and AM-d5 enantiomers in any of the tested blank urine 
samples, and quantification at the LLOQ level was within 12.2% for both enantiomers in all six 
urine sources. An extracted ion chromatogram for a blank urine specimen is shown in Fig. 2a.  
No significant changes of the ion intensities were observed in the infusion profiles of AM and 
AM-d5 after injection of blank urine samples, indicating that matrix effects were negligible.  
Any signal detected in blank specimens injected after the highest calibration standard was 
insignificant, demonstrating absence of carry-over. 
Samples spiked at concentrations exceeding the highest calibration standard could be accurately 
quantified when diluted either 5- or 10-fold in blank urine. Accuracy was better than 88.3% and 
precision was less than 4.1% CV for both AM enantiomers. 
Re-injection reproducibility was acceptable. Processed samples were within ± 14.7% of initially 
measured values when re-analyzed after storage at 8 °C for 6 days. 
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The stability of AM in urine under different storage conditions has been demonstrated previously 
[25, 30, 31] and was therefore not assessed with the presented method. 
 
Proof of applicability 
The method was applied to the analysis of 67 forensic urine samples. In each of the 40 samples 
obtained from suspected AM abusers, both AM enantiomers were present (Table 4, samples 1 - 
40). Median (range) concentrations were 3.99 mg/L (0.50 – 13.4 mg/L) for R-AM and 2.68 mg/L 
(0.46 – 9.77 mg/L) for S-AM. R/S-AM ratios were calculated as the concentration of the R-
enantiomer divided by the concentration of the S-enantiomer. The median R/S ratio was 1.25 
(0.97 – 1.94), indicating a predominance of the R-enantiomer. The expected urinary R/S ratio for 
abusers of illicit racemic AM would be 1. The observed predominance of the R-enantiomer may 
be explained by the stereoselective metabolism of AM, with the S-enantiomer being metabolized 
faster than the R-enantiomer, which results in higher concentrations of R-AM [32, 33]. In 
accordance with our observation, Tetlow et al. [6] reported an average urinary R/S ratio of 1.19 ± 
0.19 for AM abusers and Nyström et al. [34] found R/S ratios > 1 for AM in blood and hair 
samples from a patient receiving AM racemate.  
In the two urine specimens from subjects prescribed Elvanse
® 
at a dosage of 30 – 70 mg/day 
(Table 4, samples 41 and 42), S-AM concentrations were determined to be 1.51 and 1.35 mg/L, 
respectively. R-AM was undetectable in the first sample, whereas in the second sample R-AM 
was detected at a concentration of < LLOQ. Since Elvanse
®
 (lisdexamfetamine [L-lysine-
dextroamphetamine] dimesylate) is a prodrug of S-AM [35], the R-enantiomer was not expected 
to be present in these urine samples. However, the measured R-AM concentration was very low, 
suggesting that it might be due to enantiomeric impurities arising from the drug manufacture 
itself. Lisdexamfetamine is described as a single-enantiomer drug, but without providing purity 
specifications [36]. To our knowledge, enantioselective quantification of AM in biological fluids 
after lisdexamfetamine administration has not yet been performed and thus no data are available 
to confirm our assumption. As a comparison, Tetlow et al. [6] and George et al. [5] reported 
average urinary R/S-AM ratios of 0.13 and 0.08, respectively, for subjects being treated with a 
pharmaceutical preparation of S-AM which contained approximately 5% R-AM impurity. Based 
on their data they proposed that an R/S ratio < 0.3 and < 0.2, respectively, would suggest patient 
compliance. We observed an R/S ratio significantly lower than these cutoffs and thus both 
subjects were assumed to be compliant with their lisdexamfetamine treatment and abstinent from 
illicit racemic AM. Thevis et al. [37] analyzed urine samples provided by a patient receiving 30 
mg of Elvanse
®
 once-daily (corresponding to 17.3 mg of lisdexamfetamine free base) by means 
of an achiral LC-MS/MS method and reported (±)-AM concentrations of 0.04, 0.11, 0.45, and 
1.15 mg/L at 3, 6, 9, and 11 h post-administration. Therefore, we conclude that the urinary 
concentrations of the herein measured AM enantiomers are plausible.  
In 80% of the urine samples obtained from individuals suspected of MA abuse both AM 
enantiomers were detected, although a strong predominance of the S-form was observed (Table 4, 
samples 43 – 67). In these cases, the median (range) concentrations were 0.20 mg/L (< LLOQ – 
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5.69 mg/L) for R-AM and 3.57 mg/L (0.44 – 22.9 mg/L) for S-AM. R/S ratios in samples 
exhibiting concentrations above the LLOQ ranged from 0.01 to 0.47 (median 0.10). Five samples 
collected from suspected MA abusers contained only S-AM, with concentrations ranging from 
0.76 to 7.94 mg/L. The total concentrations of the AM enantiomers were in the range of those 
measured by Kumihashi et al. [38] in urine samples from MA abusers. As reported for AM, the 
S-enantiomer of MA was found to be metabolized at a greater rate than the R-enantiomer [24]. 
Thus, more S-MA is converted to S-AM than R-MA to R-AM. Keeping this in mind, the 
measured urine samples from suspected MA abusers can be classified into three groups according 
to the observed stereoisomeric profiles of AM and the assumed composition of the consumed 
MA: I) only S-AM present, this indicates misuse of pure S-MA; II) R/S ratios between 0.01 and 
0.07 or R-AM concentrations < LLOQ, this might be due to intake of S-MA containing small 
amounts of R-MA; III) R/S ratios between 0.14 and 0.47, consumption of racemic MA. This 
classification is supported by the findings reported by Li et al. [24], Nagai et al. [39] and Wang et 
al. [40]. 
From the results described here, it can be seen that the measured urinary R/S-AM ratios proved 
useful for discriminating between subjects using illicit racemic AM and those undergoing S-AM 
treatment. However, when reviewing laboratory results, it must be taken into consideration that 
the presence of AM in urine can be the result of MA metabolism. We observed that MA abuse 
can yield very similar urinary R/S-AM ratios as intake of S-AM medication. Therefore, in critical 
cases, MA should be identified as well. Careful consideration must also be given to the existence 
of AM-enantiomers eliminated in urine as the metabolites of therapeutic drugs such as selegiline 
and famprofazone [41].  
Incurred sample re-analysis was performed with a random selection of 23 authentic urine 
samples. The percentage difference between the original and analyzed R-AM concentrations was 
within 20% for 82.6 % of the repeated samples. For S-AM, 91.3% of the repeats were within 
20%. Thus, both enantiomers met the predetermined criteria, further demonstrating the reliability 
and reproducibility of the presented method. 
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Conclusion 
In this paper, a novel LC-MS/MS method for the quantification of AM enantiomers in human 
urine is described, which offers significant advantages in overall speed and simplicity over 
existing methods. The presented method proved to be sensitive, selective, accurate, and precise 
and was successfully used on authentic urine samples. The enantioselective determination of AM 
in urine can help clinicians and forensic experts to differentiate between illegal and legitimate use 
of AM. 
The chromatographic concept presented in this work allows for minimal sample pretreatment and 
increased sample throughput in chiral HPLC under isocratic conditions and thus presents an 
attractive cost-effective approach for stereoselective pharmacokinetic studies which are an 
important issue in therapeutic drug development and usually involve a large number of samples. 
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Tables 
 
Table 1 HPLC program for the quantitative analysis of amphetamine enantiomers in urine  
Time 
(min) 
Binary pump 1   
(µL/min)
a
 
Isocratic pump 
(µL/min)
b
 
Binary pump 2   
(µL/min)
c
 
Position of  
switching valve 
0.0 400 200 500 TC → waste 
1.0 400 200 500 TC → AC 
1.1 20 20 500 
 
4.9 20 20 500 TC → waste 
5.0 400 200 500 
 
6.0
d
 400 200 500 
  
TC Trapping column, AC analytical column 
a 
Mobile phase was 0.1 M aqueous ammonia/acetonitrile, 80/20; v/v 
b
 Mobile phase was 0.1 M aqueous ammonia 
c
 Mobile phase was 0.1 M aqueous ammonia/acetonitrile, 75/25; v/v 
d
 12.0 min for the last sample of an analysis sequence  
 
 
Table 2 HPLC program for column washing 
Time 
(min) 
Binary pump 1 
 
Isocratic pump 
 
Binary pump 2   
Position of  
switching valve % B 
Flow  
(µL/min) 
  
Flow  
(µL/min) 
  % B 
Flow  
(µL/min) 
  
0.0 20 400  200  25 500  TC
 → waste 
0.5 20 400  200  25 500  
 1.5 95 400  20  95 500  
 5.0 95 400  20  95 500  
 5.5 20 400  200  25 500  
 8.0 20 400   200   25 500     
TC trapping column 
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Table 3 Accuracy and precision data. Analyte concentrations of LLOQ and low, mid, and high 
QC samples were 0.05, 0.15, 4, and 20 mg/L, respectively 
QC level Intra-assay (n = 6) 
 
Inter-assay (n = 18) 
  
Accuracy  
(% Recovery) 
Precision  
(% CV) 
  
Accuracy  
(% Recovery) 
Precision  
(% CV) 
R-Amphetamine 
    
LLOQ 
 
98.0 14.1 
 
92.8 11.2 
Low 
 
92.2 5.5 
 
90.1 4.6 
Mid 
 
99.2 6.1 
 
94.8 6.6 
High 
 
99.8 4.6 
 
96.3 5.3 
       
S-Amphetamine 
    
LLOQ 
 
103.0 6.8 
 
96.4 8.7 
Low 
 
94.0 5.9 
 
91.3 4.7 
Mid 
 
93.5 10.8 
 
94.4 7.5 
High   96.9 5.3   95.1 5.9 
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Table 4 Concentrations of AM enantiomers and R/S enantiomer ratios determined in 67 urine 
samples obtained from suspected AM abusers (samples 1 – 40), subjects treated with an S-AM 
prodrug (samples 41 – 42), and suspected MA abusers (samples 43 – 67) 
Sample 
number 
R-AM  
(mg/L) 
S-AM  
(mg/L) 
R/S 
ratio  
  
Sample 
number 
R-AM  
(mg/L) 
S-AM  
(mg/L) 
R/S 
ratio  
  
Sample 
number 
R-AM  
(mg/L) 
S-AM  
(mg/L) 
R/S 
ratio  
1 1.19 0.80 1.49 
 
24 8.22 7.78 1.06 
 
47 0.16 1.11 0.14 
2 7.44 7.02 1.06 
 
25 8.79 7.08 1.24 
 
48 0.06 2.23 0.03 
3 1.54 1.40 1.10 
 
26 1.16 1.02 1.14 
 
49 < LLOQ 3.00  -  
4 8.76 6.61 1.33 
 
27 6.89 6.80 1.01 
 
50 < LLOQ 22.90  -  
5 7.41 6.61 1.12 
 
28 1.15 0.90 1.28 
 
51 0.40 13.30 0.03 
6 3.25 2.52 1.29 
 
29 9.20 7.22 1.27 
 
52 3.26 14.70 0.22 
7 2.75 2.55 1.08 
 
30 2.13 1.15 1.85 
 
53 0.23 0.50 0.47 
8 6.43 5.12 1.26 
 
31 7.46 6.04 1.24 
 
54 n.d. 2.94  -  
9 1.49 0.77 1.94 
 
32 2.33 1.85 1.26 
 
55 0.10 1.53 0.07 
10 0.82 0.72 1.14 
 
33 12.60 9.64 1.31 
 
56 n.d. 6.69  -  
11 10.80 8.17 1.32 
 
34 4.73 4.39 1.08 
 
57 5.69 22.60 0.25 
12 5.54 4.46 1.24 
 
35 5.50 3.68 1.49 
 
58 < LLOQ 0.44  -  
13 1.37 0.82 1.68 
 
36 12.20 9.77 1.25 
 
59 n.d. 0.76  -  
14 0.50 0.46 1.09 
 
37 4.03 2.52 1.60 
 
60 0.50 18.70 0.03 
15 8.28 6.44 1.29 
 
38 2.41 2.11 1.14 
 
61 0.43 20.00 0.02 
16 3.94 2.80 1.41 
 
39 1.01 0.97 1.04 
 
62 0.80 15.90 0.05 
17 13.40 8.43 1.59 
 
40 0.63 0.65 0.97 
 
63 0.60 1.45 0.41 
18 1.62 1.17 1.38 
 
41 n.d. 1.51  -  
 
64 < LLOQ 2.99  -  
19 2.32 2.36 0.98 
 
42 < LLOQ 1.35  -  
 
65 0.12 16.70 0.01 
20 6.50 5.58 1.16 
 
43 n.d. 6.40  -  
 
66 < LLOQ 1.02  -  
21 5.07 3.75 1.35 
 
44 0.34 1.75 0.19 
 
67 n.d. 7.94  -  
22 3.09 2.03 1.52 
 
45 < LLOQ 4.14  -  
 
        
23 0.60 0.55 1.09   46 1.32 6.49 0.20       
n.d. not detected, < LLOQ below limit of quantification 
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Figures 
 
Fig. 1 Configuration of the column-switching LC-MS/MS system. a Loading onto the trapping 
column and b elution to the analytical column. Arrows indicate flow direction. While 
chromatographic separation in isocratic mode is performed on one sample, the next sample is 
already loaded onto the trapping column 
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Fig. 2 SRM ion chromatograms of a blank urine (arrows indicate expected retention times), b 
analytes at the lowest calibration level (0.05 mg/L per enantiomer), c an authentic urine specimen 
from an AM abuser (R-AM, 1.54 mg/L; S-AM, 1.40 mg/L), and d an authentic urine specimen 
from a patient treated with S-AM (R-AM, 0 mg/L; S-AM, 1.51 mg/L) 
 
